Treatment class · subcategory · California
Weight Control denials at external review
When a California health plan denied care in the weight control class and the enrollee took it to Independent Medical Review, this is what independent physician reviewers decided.
87.0%
- Overturned
- 1,247 of 1,434
- Era
- 2021-2025
- Jurisdiction
- California DMHC IMR
- Published class
- Weight Control
- Median days to decision
- 42
- All years
- 86.4% of 1,578
What stands out here
computed from this classamong the highest
At 87.0%, this is the 4th highest overturn rate of the 70 treatment classes with enough decisions to publish one. Reviewers sustained the plan in the remaining 13.0% of disputes.
the question matters
The outcome turns on which question was put to the reviewer: 87.7% on medical necessity (n=1,383) against 66.7% on experimental/investigational (n=51) — a gap of 21 points inside the same treatment class.
most-cited standard
Reviewers named FDA more than any other standard here — 770 decisions, which came out at 87.1%. Citing a standard and the outcome share a cause; this is not the effect of naming it.
concentrated
94% of these disputes involved endocrine & metabolic alone (n=1,350, 87.7% overturned), so the headline figure for weight control is largely that pairing.
The trend, with its era
computedHover the chart for a year’s counts. Series stops at 2025 — report year 2026 uses a different category vocabulary.
What reviewers relied on
3 validated codesCalifornia requires each published decision to carry “a detailed case summary that includes the specific standards, criteria, and medical and scientific evidence, if any, that led to the case decision” (Health & Safety Code § 1374.33(h)(1)(K)). These are the elements our extraction found in this class, split by how the decision came out.
| What the reviewer relied on | In overturns | In upholds |
|---|---|---|
| the FDA label or approval status | 54%n=1,247 | 55%n=187 |
| a standardised level-of-care instrument | 0%n=1,247 | 0%n=187 |
| a California statutory definition | 0%n=1,247 | 0%n=187 |
Read as description, not instruction. These are patterns in what reviewers wrote, not steps to follow, and no combination of them predicts an outcome. Only codes that cleared the validation gate appear — thirteen did not.
Authorities named in this class
computed- FDA87.1%770
- American Gastroenterological Association—25
- American Diabetes Association—14
- American Academy of Pediatrics—4
- American Headache Society—1
A rate here is the outcome of decisions that named the authority, not the effect of naming it. Reviewers cite the standard they applied; the citation and the outcome share a cause.
By condition
computed- Overturned — the reviewer did not sustain the denial
- Upheld — the reviewer sustained the denial
- Endocrine & metabolic87.7%1,350
- Cardiac & circulatory75.0%32
- CNS & neuromuscular—17
- Genitourinary & kidney—15
- Digestive & GI—5
- Immune disorders—5
- Mental health—3
- Blood disorders—2
The specific conditions inside this class
below n=30, no rate is claimed- Obesity89.3%1,230
- Diabetes72.1%68
- Other68.6%35
- Hypertension—20
- Apnea/Sleep Apnea—15
- High Cholesterol—10
- Hormone Abnormality—8
- Ovarian Cyst—8
By review type
computed- Medical Necessity87.7%1,383
- Experimental/Investigational66.7%51
Medical-necessity review asks whether the care is needed. Experimental/investigational review asks whether it is likely to be more beneficial than standard therapy — a harder statutory test, and the rates show it.
Every figure on this page is conditional on a denial having reached external review. Fewer than 1% of denials are appealed internally at all, so this describes denials that were fought to the end — not denials in general — and it describes California only. Who this does not cover.
Free help, first: the California DMHC Help Center files your Independent Medical Review at no cost — 1-888-466-2219, dmhc.ca.gov.